HITIQ Ltd (ASX:HIQ) Announces Partnership with AFL Barwon to Expand PROTEQT
A three-year partnership with AFL Barwon aims to expand HITIQ’s PROTEQT concussion management technology to over 25,000 players in regional Victoria.
Category: Healthcare
Neuren Pharmaceuticals (ASX:NEU) Reports Record Financial Performance and Expansion Plans
Neuren Pharmaceuticals (ASX:NEU) reports a record A$166m income in 2024, driven by DAYBUE sales and initiates Phase 3 trials for NNZ-2591.
Imugene Limited (ASX:IMU) Announces Extraordinary General Meeting
Imugene Limited (ASX:IMU) announces an Extraordinary General Meeting to discuss share consolidation and the issuance of new shares to support its clinical projects.
Recce Pharmaceuticals (ASX:RCE) Secures China Patent for Anti-Infectives
Recce Pharmaceuticals (ASX:RCE) secures a China Patent for its RECCE® anti-infectives, enhancing its global intellectual property portfolio.
OncoSil Medical Limited (ASX:OSL) Announces $8.7M Capital Raise to Drive Commercialisation
OncoSil Medical (ASX:OSL) secures $8.7 million in capital to advance commercialisation and support ongoing clinical trials.
Dimerix (ASX:DXB) Successfully Completes IDMC Review for ACTION3 Phase 3 Trial
Dimerix (ASX:DXB) successfully completes IDMC review of ACTION3 Phase 3 trial, affirming DMX-200’s safety profile.
AFT Pharmaceuticals (ASX:AFP) Reports Record Annual Revenue
AFT Pharmaceuticals (ASX:AFP) reports a 6% increase in FY25 revenue, targets $300M by FY27, and declares an increased dividend.
Oceania Healthcare (ASX:OCA) Reports FY25 Results and Strategic Initiatives
Oceania Healthcare (ASX:OCA) reports FY25 results, highlighting financial performance and strategic initiatives for future growth.
Chimeric Therapeutics (ASX:CHM) Announces $6.6 Million Placement to Advance Clinical Trials
Chimeric Therapeutics (ASX:CHM) announces a $6.6 million placement to fund key clinical trials in its cell therapy pipeline.
Monash IVF Group (ASX:MVF) Updates FY25 Profit Guidance
Monash IVF Group (ASX:MVF) revises FY25 Underlying NPAT guidance to $27.5m, reflecting softer market conditions.